Core Viewpoint - Catalyst Pharmaceuticals, Inc. is set to release its fourth quarter and full-year 2024 financial results on February 26, 2025, followed by a conference call on February 27, 2025, to discuss these results and provide a business update [1][2]. Company Overview - Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing novel medicines for patients with rare and difficult-to-treat diseases [1][4]. - The company has a proven track record of bringing life-changing treatments to market and emphasizes patient care and accessibility through comprehensive support services [4]. - Catalyst is headquartered in Coral Gables, FL, and has been recognized on the Forbes 2025 list as one of America's most successful mid-cap companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America's fastest-growing companies [4]. Conference Call & Webcast Details - The conference call and webcast will take place on February 27, 2025, at 8:30 AM ET, with dial-in numbers provided for US/Canada and international participants [2][3]. - The webcast will be accessible on the company's website, and a replay will be available for at least 30 days following the event [3].

Core Viewpoint - The content emphasizes the importance of conducting personal due diligence and consulting competent advisors before making any financial decisions, particularly in the context of investments and trading [1]. Group 1 - The website provides general news, personal analysis, and third-party content intended for educational and research purposes [1]. - It explicitly states that the information does not constitute any recommendation or advice for investment actions [1]. - Users are advised to perform their own research and consider their financial situation before making decisions [1]. Group 2 - The website includes information about complex financial instruments such as cryptocurrencies and contracts for difference (CFDs), which carry a high risk of losing money [1]. - It encourages users to understand how these instruments work and the associated risks before investing [1].

Core Insights - Catalyst Pharmaceuticals, Inc. has been ranked fifth in Forbes' list of America's Most Successful Mid-Cap Companies for 2025, showcasing its strong performance among 100 companies [1][2][3] - The ranking reflects Catalyst's continued growth, moving from fourth place in the previous year's list of Small-Cap Companies, indicating a positive trajectory in earnings, sales, return on equity, and total stock return over the last five years [2][3] Company Overview - Catalyst Pharmaceuticals is a biopharmaceutical company focused on improving the lives of patients with rare diseases, emphasizing the development and commercialization of innovative therapies [4] - The company has a strong commitment to patient care and accessibility, providing a comprehensive suite of support services to ensure patients receive necessary treatments [4] - Catalyst is headquartered in Coral Gables, Florida, and is actively seeking to expand its global presence through strategic partnerships, while also being recognized as one of North America's Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List [4]

Core Insights - Catalyst Pharmaceuticals has announced the launch of FIRDAPSE® (amifampridine) Tablets 10 mg in Japan by its sub-licensee DyDo Pharma, aimed at improving muscle weakness in patients with Lambert-Eaton myasthenic syndrome (LEMS) [1][2] Company Overview - Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases, with a commitment to patient care and accessibility [6] - The company has a strong presence in the U.S. and is actively seeking to expand its global footprint through strategic partnerships [6] Product Information - FIRDAPSE is the only FDA-approved therapy for LEMS in adults and pediatric patients aged six years and older, characterized as a rare autoimmune disorder [2][3] - The mechanism of action for FIRDAPSE involves blocking potassium channels, enhancing neuromuscular transmission, and improving muscle function [3] Market Expansion - The launch of FIRDAPSE in Japan represents a significant step in expanding the geographic reach of Catalyst's product portfolio, enhancing access to life-changing therapies for patients in Japan [2][6] - DyDo Pharma, a wholly-owned subsidiary of DyDo Group Holdings, is responsible for the commercialization of FIRDAPSE in Japan [5]

Core Viewpoint - Catalyst Pharmaceuticals has reached a settlement with Teva Pharmaceuticals regarding the patent litigation for Firdapse, which has positively impacted its stock price, increasing by 16.7% [1][5]. Group 1: Settlement Agreement - The settlement resolves the patent litigation initiated by Catalyst and SERB against Teva for filing an abbreviated new drug application (ANDA) for a generic version of Firdapse before the expiration of applicable patents [2]. - Teva has agreed not to market its generic version of Firdapse in the U.S. before February 25, 2035, unless specific exceptions arise [5]. - Ongoing litigation against other defendants, such as Hetero and Lupin, continues regarding Firdapse patents [6]. Group 2: Product Performance - Firdapse is currently approved in the U.S., EU, and Japan for treating Lambert-Eaton Myasthenic Syndrome (LEMS) in adults, with a label expansion for pediatric patients approved in 2022 [3]. - Firdapse accounted for 65% of Catalyst's net product sales in 2023, generating $223.5 million in revenues in the first nine months of 2024 [8]. - Catalyst also markets two other drugs, Fycompa and Agamree, which provide additional revenue streams [9]. Group 3: Recent Developments - Catalyst acquired U.S. rights for Fycompa from Eisai and North American rights for vamorolone from Santhera Pharma in 2023 [10]. - Catalyst's stock has outperformed the industry, gaining 14.5% over the past three months compared to a 7.7% decline in the industry [4].

Core Viewpoint - The article emphasizes the importance of confirming the sustainability of stock trends for successful short-term investing, highlighting that price movements should be supported by strong fundamentals and positive earnings estimates [1][2]. Group 1: Stock Performance - Catalyst Pharmaceutical (CPRX) has shown a solid price increase of 5.2% over the past 12 weeks, indicating investor confidence in its potential upside [4]. - The stock has also maintained a price increase of 3.8% over the last four weeks, suggesting that the upward trend is still intact [5]. - CPRX is currently trading at 86.8% of its 52-week high-low range, indicating a potential breakout opportunity [5]. Group 2: Fundamental Strength - CPRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [7]. Group 3: Investment Strategy - The article suggests that investors can utilize the "Recent Price Strength" screen to identify stocks like CPRX that are on an uptrend supported by strong fundamentals [3]. - There are over 45 Zacks Premium Screens available for investors to find stocks that align with their personal investing styles [8].

Company Overview - Catalyst Pharmaceutical (CPRX) shares increased by 16.7% to close at $22.80, following a notable trading volume that exceeded typical levels [1] - The stock had previously experienced an 11.7% decline over the past four weeks [1] Recent Developments - The rise in stock price was linked to a settlement agreement with Teva Pharmaceuticals regarding patent litigation for Firdapse (amifampridine), resolving issues related to Teva's abbreviated new drug application for a generic version [2] Financial Expectations - Catalyst is projected to report quarterly earnings of $0.52 per share, reflecting a year-over-year decrease of 1.9%, while revenues are expected to reach $132.71 million, marking a 20% increase from the previous year [3] - The consensus EPS estimate for Catalyst has remained unchanged over the last 30 days, indicating stability in earnings expectations [4] Industry Context - Catalyst operates within the Zacks Medical - Drugs industry, where Ionis Pharmaceuticals (IONS) has seen a 2.5% decline in its stock price, with a return of -8.6% over the past month [4] - Ionis Pharmaceuticals has a consensus EPS estimate of -$1.13, which represents a significant year-over-year decline of 1783.3% [5]

Core Viewpoint - Catalyst Pharmaceuticals has entered into a Settlement Agreement with Teva Pharmaceuticals to resolve patent litigation regarding the generic version of FIRDAPSE, ensuring that Teva cannot market its generic version before February 25, 2035, if approved by the FDA [1][2]. Company Overview - Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, with a commitment to patient care and accessibility [4]. - The company has a strong presence in the U.S. and is actively seeking to expand its global footprint through strategic partnerships [4]. - Catalyst was recognized as one of North America's Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List [4]. Legal and Regulatory Aspects - The Settlement Agreement will terminate all ongoing patent litigation between Catalyst/SERB and Teva regarding FIRDAPSE patents in the U.S. District Court for the District of New Jersey [2]. - The confidential license agreement will be submitted to the U.S. Federal Trade Commission and the U.S. Department of Justice for review as required by law [3].

Core Viewpoint - The article discusses the Zacks Style Scores, which are designed to help investors identify stocks with the best chances of outperforming the market over the next 30 days, focusing on growth, momentum, and value characteristics. Group 1: Zacks Style Scores Overview - The Zacks Style Scores are categorized into four types: Growth Score, Momentum Score, Value Score, and VGM Score, each assessing different aspects of a stock's performance [2][10][19]. - Each stock is rated from A to F based on its value, growth, and momentum characteristics, with A being the highest score indicating a better chance of outperforming [9]. - The Style Scores are intended to complement the Zacks Rank, which is based on earnings estimate revisions, to aid in stock selection [5][20]. Group 2: Catalyst Pharmaceuticals (CPRX) Analysis - Catalyst Pharmaceuticals, Inc. (CPRX) is highlighted as a stock to watch, currently holding a Momentum Style Score of B and experiencing a 1.9% increase in share price over the past four weeks [6][16]. - CPRX has a Zacks Rank of 3 (Hold) and a VGM Score of A, indicating a solid position among stocks [15][16]. - For fiscal 2024, five analysts have revised their earnings estimates upwards, with the Zacks Consensus Estimate increasing by $0.10 to $2.02 per share, and CPRX has an average earnings surprise of 18% [24].

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? Developed alon ...